A Systematic Review Evaluating the Effectiveness of Several Biological Therapies for the Treatment of Skin Psoriasis

被引:4
作者
Alzahrani, Sattam A. [1 ]
Alzamil, Fajer M. [2 ]
Aljuhni, Abdulaziz M. [1 ]
Thaqfan, Naif A. Al [1 ]
Alqahtani, Norah Y. [1 ,3 ]
Alwarwari, Sara A. [4 ]
Alkharashi, Abdullah A. [1 ]
Alzabadin, Rakan A. [1 ]
Alzehairi, Reema A.
Alhajlah, Abdullah A. [1 ,5 ]
机构
[1] Al Imam Mohammed Bin Saud Islamic Univ, Gen Practice, Riyadh, Saudi Arabia
[2] Imam Mohammed Bin Saud Islamic Univ, Coll Med, Dermatol, Riyadh, Saudi Arabia
[3] Princess Nourah Bint Abdulrahman Univ, Gen Practice, Riyadh, Saudi Arabia
[4] Vis Coll, Gen Practice, Riyadh, Saudi Arabia
[5] King Saud Bin Abdulaziz Univ Hlth Sci, Dermatol, Coll Med, Riyadh, Saudi Arabia
关键词
biologic treatment; dermatology; effectiveness; biological therapies; psoriasis; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; TO-SEVERE PSORIASIS; DOUBLE-BLIND; PLAQUE PSORIASIS; PHASE-III; NAIVE PATIENTS; VOYAGE; PLACEBO; MODERATE; SAFETY;
D O I
10.7759/cureus.50588
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Psoriasis is a chronic inflammatory skin illness that has the potential to manifest at any stage of life, it is most frequently observed in early adulthood. Biological drugs have significantly transformed the landscape of psoriasis treatment through the provision of focused therapy, which effectively mitigates inflammation and regulates the overproduction of skin cells. Notwithstanding the accessibility of these biological drugs, rigorous evaluations that juxtapose their safety and efficacy profiles are necessary. The objective of this study is to conduct a thorough investigation of the relative efficacy of these drugs in alleviating psoriasis symptoms and increasing the quality of life for patients by synthesizing the existing evidence. A comprehensive review was conducted to evaluate and compare the safety and effectiveness of different biochemical medicines utilized in the management of psoriasis. In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations, the review process was conducted among the available studies. A search was conducted across electronic databases, such as Web of Science, PubMed, and Embase, utilizing a combination of keywords and Mesh phrases pertaining to psoriasis, biological medications, and particular names of pharmaceuticals. In total, 475 studies were ascertained by the preliminary search of the database. After eliminating duplicate research, 358 distinct studies remained. After meticulous screening of titles and abstracts against the predefined inclusion criteria, 281 papers were deemed ineligible and thus excluded. For final inclusion, the whole texts of the remaining 77 studies were evaluated. Forty additional papers were removed during the full-text evaluation for a variety of reasons, including improper research design, or insufficient outcome data. Finally, 37 studies were included in this systematic review since they satisfied all inclusion criteria. The results of the current systematic review showed that all biological medications showed high efficacy in the treatment of skin psoriasis compared with placebo based on the clinical assessment outcomes using different tools such as PASI.
引用
收藏
页数:20
相关论文
共 66 条
[1]   Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial [J].
Antoni, C ;
Krueger, GG ;
de Vlam, K ;
Birbara, C ;
Beutler, A ;
Guzzo, C ;
Zhou, B ;
Dooley, LT ;
Kavanaugh, A .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1150-1157
[2]   Comparison of Biologics and Oral Treatments for Plaque Psoriasis A Meta-analysis [J].
Armstrong, April W. ;
Puig, Luis ;
Joshi, Avani ;
Skup, Martha ;
Williams, David ;
Li, Junlong ;
Betts, Keith A. ;
Augustin, Matthias .
JAMA DERMATOLOGY, 2020, 156 (03) :258-269
[3]   Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience [J].
Arroyo-Andres, J. ;
Falkenhain-Lopez, D. ;
Agud-Dios, M. ;
Rivera-Diaz, R. .
ACTAS DERMO-SIFILIOGRAFICAS, 2023, 114 (04) :T363-T365
[4]   Current knowledge on psoriasis and autoimmune diseases [J].
Ayala-Fontanez, Nilmarie ;
Soler, David C. ;
McCormick, Thomas S. .
PSORIASIS-TARGETS AND THERAPY, 2016, 6 :7-32
[5]   Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results) [J].
Bagel, Jerry ;
Nia, John ;
Hashim, Peter W. ;
Patekar, Manmath ;
de Vera, Ana ;
Hugot, Sophie ;
Sheng, Kuan ;
Xia, Summer ;
Gilloteau, Isabelle ;
Muscianisi, Elisa ;
Blauvelt, Andrew ;
Lebwohl, Mark .
DERMATOLOGY AND THERAPY, 2018, 8 (04) :571-579
[6]   Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study [J].
Baranauskaite, Asta ;
Raffayova, Helena ;
Kungurov, N. V. ;
Kubanova, Anna ;
Venalis, Algirdas ;
Helmle, Laszlo ;
Srinivasan, Shankar ;
Nasonov, Evgeny ;
Vastesaeger, Nathan .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (04) :541-548
[7]   Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) [J].
Barker, J. ;
Hoffmann, M. ;
Wozel, G. ;
Ortonne, J. -P. ;
Zheng, H. ;
van Hoogstraten, H. ;
Reich, K. .
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (05) :1109-1117
[8]   Quality of life in patients with psoriasis [J].
Bhosle, Monali J. ;
Kulkarni, Amit ;
Feldman, Steven R. ;
Balkrishnan, Rajesh .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)
[9]   Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3) [J].
Blauvelt, Andrew ;
Gooderham, Melinda ;
Iversen, Lars ;
Ball, Susan ;
Zhang, Lu ;
Agada, Noah O. ;
Reich, Kristian .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (05) :855-862
[10]   Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial [J].
Blauvelt, Andrew ;
Papp, Kim A. ;
Griffiths, Christopher E. M. ;
Randazzo, Bruce ;
Wasfi, Yasmine ;
Shen, Yaung-Kaung ;
Li, Shu ;
Kimball, Alexa B. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) :405-417